Figure 1 (IMAGE) Shinshu University Caption The EGFR-mediated pathway, which is not targeted by lenvatinib, is activated for survival in thyroid cancer cells under the potent inhibition of the VEGFR and FGFR families by lenvatinib. Credit KEN-ICHI ITO, SHINSHU UNIVERSITY Usage Restrictions Credit must be given to the creator. License Original content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.